Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AgomAb Therapeutics NV ADR ( (AGMB) ) has shared an update.
AgomAb Therapeutics NV, a Belgium-based clinical-stage biopharmaceutical company focused on disease-modifying therapies for immunology and inflammatory diseases, particularly chronic fibrotic indications, is pursuing a strategy centered on targeting validated pathways to overcome limitations of prior treatments. The company’s mission is to develop therapeutics that resolve fibrosis and restore organ function so patients can live fuller and healthier lives.
On February 9, 2026, AgomAb closed its initial public offering of 12,500,000 American Depositary Shares in the United States, following the IPO launch on February 2 and pricing announcement on February 5. In connection with the listing of its ADSs on the Nasdaq Global Select Market under the symbol AGMB, AgomAb’s amended and restated articles of association became effective, marking a key capital markets milestone that is expected to strengthen its financial base and visibility as it advances its clinical pipeline.
More about AgomAb Therapeutics NV ADR
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic conditions with high unmet medical need. Its product candidates aim to target established biological pathways using validated modalities to enhance efficacy while minimizing systemic toxicities, with the goal of resolving fibrosis and restoring organ function.
Average Trading Volume: 2,362,250
Current Market Cap: $366.3K
For detailed information about AGMB stock, go to TipRanks’ Stock Analysis page.